The Global Pharmaceutical Intermediates Market Size accounted for USD 30.9 Billion in 2022 and is estimated to achieve a market size of USD 55.8 Billion by 2032 growing at a CAGR of 6.2% from 2023 to 2032.
Pharmaceutical Intermediates Market Highlights
- Global pharmaceutical intermediates market revenue is poised to garner USD 55.8 billion by 2032 with a CAGR of 6.2% from 2023 to 2032
- North America pharmaceutical intermediates market value occupied more than USD 9.3 billion in 2022
- Asia-Pacific pharmaceutical intermediates market growth will record a CAGR of around 7% from 2023 to 2032
- Among type, the GMP sub-segment generated over US$ 18.5 billion revenue in 2022
- Based end-user, the packaging sub-segment generated around 40% share in 2022
- Growing popularity of personalized medicine is a popular pharmaceutical intermediates market trend that fuels the industry demand
Pharmaceutical intermediates are the chemical composites that are major ingredients exploited in the manufacturing of active pharmaceutical ingredients. Pharmaceutical intermediates are formed at the time of the process of production or synthesis of active pharmaceutical ingredients. These pharmaceutical intermediates later endure molecular changes and processing before becoming vigorous pharmaceutical ingredients.
Global Pharmaceutical Intermediates Market Dynamics
Market Drivers
- Increasing demand for generic drugs
- Growth in the pharmaceutical industry
- Surging investment in research and development
- Rising healthcare expenditure
Market Restraints
- Stringent regulations
- High capital investment
- Competition from low-cost countries
Market Opportunities
- Outsourcing of manufacturing
- Increasing demand for biotech-based intermediates
- Focus on innovation and research
Pharmaceutical Intermediates Market Report Coverage
Market |
Pharmaceutical Intermediates Market |
Pharmaceutical Intermediates Market Size 2022 |
USD 30.9 Billion |
Pharmaceutical Intermediates Market Forecast 2032 |
USD 55.8 Billion |
Pharmaceutical Intermediates Market CAGR During 2023 - 2032 |
6.2% |
Pharmaceutical Intermediates Market Analysis Period |
2020 - 2032 |
Pharmaceutical Intermediates Market Base Year |
2022 |
Pharmaceutical Intermediates Market Forecast Data |
2023 - 2032 |
Segments Covered |
By Type, By Structure Building Blocks, By End-User, And By Geography
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
Key Companies Profiled |
Aceto Corporation, A.R. Life Sciences Private Limited, BASF SE, Chemcon Speciality Chemicals Ltd. Midas Pharma GmbH, Codexis, Inc., Cycle Pharmaceuticals, Dextra Laboratories Ltd, Dishman Group, Easter Chemical Corporation, Pvt. Ltd., Lianhe Chemical Technology Co., Ltd., Sanofi Winthrop Industries, Vertellus Holdings LLC, and ZCL Chemical Ltd.
|
Report Coverage
|
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Covid-19 Analysis, Regulation Analysis |
Pharmaceutical Intermediates Market Insights
The pharmaceutical industry is one of the rapidly nurturing industries, globally. As pharmaceutical intermediates are the fundamental base part of active pharmaceutical ingredients (APIs), the market for API is also expected to witness an upsurge in demand in the foreseeable years. API market is very vigorous and in the last few years, there has been a drastic inclination in the direction of research and development activities. Owing to the growth in the R&D sector, the pharmaceutical intermediates market is projected to reflect drastic growth. However, rising monetary pressure as well as the regulatory obstruction is expected to freeze the growth of the pharmaceutical intermediates market.
Pharmaceutical Intermediates Market, By Segmentation
The worldwide market for pharmaceutical intermediates is split based on type, structure building blocks, end-user, and geography.
Pharmaceutical Intermediates Market, By Type
According to pharmaceutical intermediates industry analysis, GMP (good manufacturing practice) intermediates dominate the market. Before they are used in the production of final drug products, GMP intermediates are subjected to rigorous testing and inspection in accordance with strict quality standards. GMP intermediates ensure the final drug product's safety, efficacy, and quality and are required by regulatory agencies such as the FDA (Food and Drug Administration) in the United States.
Non-GMP (non-good manufacturing practise) intermediates, on the other hand, are produced without adhering to the same stringent quality standards and may not be subjected to the same level of testing and inspection as GMP intermediates. Non-GMP intermediates are frequently used in early-stage research and development and are not intended for use in the production of finished pharmaceutical products.
Pharmaceutical Intermediates Market, By Structure Building Blocks
- Achiral Building Blocks
- Chiral Building Blocks
Chiral building blocks will have a higher demand and a larger market share in 2022 than achiral building blocks. Chiral building blocks are organic compounds with an asymmetric carbon centre that exist in two mirror image enantiomeric forms. They are essential in the synthesis of chiral drugs, which have a specific 3D structure and are only active in one of the enantiomeric forms. Chiral building blocks are important in drug development because they are used to create the desired stereochemistry in the final drug molecule.
Achiral building blocks, on the other hand, are organic compounds that do not have an asymmetric carbon centre and exist as a single entity. They are used in the synthesis of a variety of medications and are typically used in the early stages of drug development. Achiral building blocks are used to construct the basic skeleton of the drug molecule and thus play an important role in the drug synthesis process.
Pharmaceutical Intermediates Market, By End-User
- Pharmaceutical Companies
- Contract Manufacturing Organizations (CMOs)
- Research Organizations
Pharmaceutical companies are expected to dominate the pharmaceutical intermediates market from 2023 to 2032, according to market forecasts. Pharmaceutical companies develop, manufacture, and market drugs, and they require a steady supply of pharmaceutical intermediates to support their operations. These intermediates are crucial for the synthesis of other chemical compounds, such as active pharmaceutical ingredients (APIs), which serve as the building blocks for pharmaceutical products.
Contract manufacturing organisations (CMOs) are important users of pharmaceutical intermediates. CMOs are third-party companies that provide pharmaceutical companies with manufacturing services and are in charge of producing APIs, pharmaceutical intermediates, and finished drug products,. Another end-user of pharmaceutical intermediates is research organisations.
These organisations work in drug discovery and development, and they require pharmaceutical intermediates for early-stage research and development. Pharmaceutical intermediates are typically required in small quantities by research organisations, and larger quantities may be contracted out to CMOs or pharmaceutical companies.
Pharmaceutical Intermediates Market Regional Outlook
North America
Europe
- U.K.
- Germany
- France
- Spain
- Rest of Europe
Asia-Pacific
- India
- Japan
- China
- Australia
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
The Middle East & Africa
- South Africa
- GCC Countries
- Rest of the Middle East & Africa (ME&A)
Pharmaceutical Intermediates Market Regional Analysis
A large number of pharmaceutical companies are present in North America, and there is a high demand for drugs, making it one of the largest markets for pharmaceutical intermediates. The United States is the largest market in North America, with growth fueled by a well-established pharmaceutical industry, rising demand for specialty drugs, and increased R&D investments.
Europe is another significant market for pharmaceutical intermediates, with the United Kingdom, Germany, and France leading the way. Increased demand for innovative drugs, increased awareness of personalized medicine, and increased investments in research and development are driving growth in Europe.
The Asia-Pacific region has the fastest-growing market for pharmaceutical intermediates, led by China, India, and Japan. The presence of a large number of contract manufacturing organizations, low labor costs, and increasing investments in research and development are driving growth in the region.
Pharmaceutical Intermediates Market Players
Some of the top pharmaceutical intermediates companies offered in the professional report include Aceto Corporation, A.R. Life Sciences Private Limited, BASF SE, Chemcon Speciality Chemicals Ltd. Midas Pharma GmbH, Codexis, Inc., Cycle Pharmaceuticals, Dextra Laboratories Ltd, Dishman Group, Easter Chemical Corporation, Pvt. Ltd., Lianhe Chemical Technology Co., Ltd., Sanofi Winthrop Industries, Vertellus Holdings LLC, and ZCL Chemical Ltd.
CHAPTER 1. Industry Overview of Pharmaceutical Intermediates Market
1.1. Definition and Scope
1.1.1. Definition of Pharmaceutical Intermediates
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Pharmaceutical Intermediates Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Pharmaceutical Intermediates Market By Type
1.2.3. Pharmaceutical Intermediates Market By Structure Building Blocks
1.2.4. Pharmaceutical Intermediates Market By End-User
1.2.5. Pharmaceutical Intermediates Market By Region
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restraint 1
3.2.2. Restraint 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Pharmaceutical Companies of Suppliers
3.4.2. Bargaining Pharmaceutical Companies of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Pharmaceutical Intermediates Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Pharmaceutical Intermediates Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Regulatory Compliance
3.9. Competitive Landscape, 2022
3.9.1. Player Positioning Analysis
3.9.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Pharmaceutical Intermediates Market By Type
4.1. Introduction
4.2. Pharmaceutical Intermediates Revenue By Type
4.2.1. Pharmaceutical Intermediates Revenue (USD Billion) and Forecast, By Type, 2020-2032
4.2.2. GMP
4.2.2.1. GMP Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
4.2.3. Non-GMP
4.2.3.1. Non-GMP Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 5. Pharmaceutical Intermediates Market By Structure Building Blocks
5.1. Introduction
5.2. Pharmaceutical Intermediates Revenue By Structure Building Blocks
5.2.1. Pharmaceutical Intermediates Revenue (USD Billion) and Forecast, By Structure Building Blocks, 2020-2032
5.2.2. Achiral Building Blocks
5.2.2.1. Achiral Building Blocks Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.3. Chiral Building Blocks
5.2.3.1. Chiral Building Blocks Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 6. Pharmaceutical Intermediates Market By End-User
6.1. Introduction
6.2. Pharmaceutical Intermediates Revenue By End-User
6.2.1. Pharmaceutical Intermediates Revenue (USD Billion) and Forecast, By End-User, 2020-2032
6.2.2. Pharmaceutical Companies
6.2.2.1. Pharmaceutical Companies Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.3. Contract Manufacturing Organizations (CMOs)
6.2.3.1. Contract Manufacturing Organizations (CMOs) Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.4. Research Organizations
6.2.4.1. Research Organizations Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 7. North America Pharmaceutical Intermediates Market By Country
7.1. North America Pharmaceutical Intermediates Market Overview
7.2. U.S.
7.2.1. U.S. Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By Type, 2020-2032
7.2.2. U.S. Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By Structure Building Blocks, 2020-2032
7.2.3. U.S. Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By End-User, 2020-2032
7.3. Canada
7.3.1. Canada Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By Type, 2020-2032
7.3.2. Canada Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By Structure Building Blocks, 2020-2032
7.3.3. Canada Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By End-User, 2020-2032
7.4. North America PEST Analysis
CHAPTER 8. Europe Pharmaceutical Intermediates Market By Country
8.1. Europe Pharmaceutical Intermediates Market Overview
8.2. U.K.
8.2.1. U.K. Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By Type, 2020-2032
8.2.2. Canada Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By Structure Building Blocks, 2020-2032
8.2.3. U.K. Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By End-User, 2020-2032
8.3. Germany
8.3.1. Germany Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By Type, 2020-2032
8.3.2. Germany Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By Structure Building Blocks, 2020-2032
8.3.3. Germany Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By End-User, 2020-2032
8.4. France
8.4.1. France Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By Type, 2020-2032
8.4.2. France Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By Structure Building Blocks, 2020-2032
8.4.3. France Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By End-User, 2020-2032
8.5. Spain
8.5.1. Spain Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By Type, 2020-2032
8.5.2. Spain Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By Structure Building Blocks, 2020-2032
8.5.3. Spain Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By End-User, 2020-2032
8.6. Rest of Europe
8.6.1. Rest of Europe Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By Type, 2020-2032
8.6.2. Rest of Europe Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By Structure Building Blocks, 2020-2032
8.6.3. Rest of Europe Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By End-User, 2020-2032
8.7. Europe PEST Analysis
CHAPTER 9. Asia Pacific Pharmaceutical Intermediates Market By Country
9.1. Asia Pacific Pharmaceutical Intermediates Market Overview
9.2. China
9.2.1. China Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By Type, 2020-2032
9.2.2. China Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By Structure Building Blocks, 2020-2032
9.2.3. China Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By End-User, 2020-2032
9.3. Japan
9.3.1. Japan Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By Type, 2020-2032
9.3.2. Japan Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By Structure Building Blocks, 2020-2032
9.3.3. Japan Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By End-User, 2020-2032
9.4. India
9.4.1. India Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By Type, 2020-2032
9.4.2. India Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By Structure Building Blocks, 2020-2032
9.4.3. India Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By End-User, 2020-2032
9.5. Australia
9.5.1. Australia Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By Type, 2020-2032
9.5.2. Australia Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By Structure Building Blocks, 2020-2032
9.5.3. Australia Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By End-User, 2020-2032
9.6. South Korea
9.6.1. South Korea Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By Type, 2020-2032
9.6.2. South Korea Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By Structure Building Blocks, 2020-2032
9.6.3. South Korea Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By End-User, 2020-2032
9.7. Rest of Asia-Pacific
9.7.1. Rest of Asia-Pacific Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By Type, 2020-2032
9.7.2. Rest of Asia-Pacific Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By Structure Building Blocks, 2020-2032
9.7.3. Rest of Asia-Pacific Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By End-User, 2020-2032
9.8. Asia Pacific PEST Analysis
CHAPTER 10. Latin America Pharmaceutical Intermediates Market By Country
10.1. Latin America Pharmaceutical Intermediates Market Overview
10.2. Brazil
10.2.1. Brazil Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By Type, 2020-2032
10.2.2. Brazil Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By Structure Building Blocks, 2020-2032
10.2.3. Brazil Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By End-User, 2020-2032
10.3. Mexico
10.3.1. Mexico Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By Type, 2020-2032
10.3.2. Mexico Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By Structure Building Blocks, 2020-2032
10.3.3. Mexico Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By End-User, 2020-2032
10.4. Rest of Latin America
10.4.1. Rest of Latin America Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By Type, 2020-2032
10.4.2. Rest of Latin America Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By Structure Building Blocks, 2020-2032
10.4.3. Rest of Latin America Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By End-User, 2020-2032
10.5. Latin America PEST Analysis
CHAPTER 11. Middle East & Africa Pharmaceutical Intermediates Market By Country
11.1. Middle East & Africa Pharmaceutical Intermediates Market Overview
11.2. GCC
11.2.1. GCC Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By Type, 2020-2032
11.2.2. GCC Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By Structure Building Blocks, 2020-2032
11.2.3. GCC Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By End-User, 2020-2032
11.3. South Africa
11.3.1. South Africa Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By Type, 2020-2032
11.3.2. South Africa Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By Structure Building Blocks, 2020-2032
11.3.3. South Africa Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By End-User, 2020-2032
11.4. Rest of Middle East & Africa
11.4.1. Rest of Middle East & Africa Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By Type, 2020-2032
11.4.2. Rest of Middle East & Africa Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By Structure Building Blocks, 2020-2032
11.4.3. Rest of Middle East & Africa Pharmaceutical Intermediates Revenue (USD Billion) and Forecast By End-User, 2020-2032
11.5. Middle East & Africa PEST Analysis
CHAPTER 12. Player Analysis Of Pharmaceutical Intermediates Market
12.1. Pharmaceutical Intermediates Market Company Share Analysis
12.2. Competition Matrix
12.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
12.2.2. New Product Launches and Product Enhancements
12.2.3. Mergers And Acquisition In Global Pharmaceutical Intermediates Market
12.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 13. Company Profile
13.1. Aceto Corporation
13.1.1. Company Snapshot
13.1.2. Business Overview
13.1.3. Financial Overview
13.1.3.1. Revenue (USD Billion), 2022
13.1.3.2. Aceto Corporation 2022 Pharmaceutical Intermediates Business Regional Distribution
13.1.4. Product /Service and Specification
13.1.5. Recent Developments & Business Strategy
13.2. A.R. Life Sciences Private Limited
13.3. BASF SE
13.4. Chemcon Speciality Chemicals Ltd.
13.5. Codexis, Inc.
13.6. Cycle Pharmaceuticals
13.7. Dextra Laboratories Ltd
13.8. Dishman Group
13.9. Easter Chemical Corporation, Pvt. Ltd.
13.10. Lianhe Chemical Technology Co., Ltd.
13.11. Midas Pharma GmbH
13.12. Sanofi Winthrop Industries
13.13. Vertellus Holdings LLC
13.14. ZCL Chemical Ltd.